Intravenous and intramuscular pharmacokinetics of recombinant leukocyte a interferon
- 1 January 1985
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 28 (4) , 469-471
- https://doi.org/10.1007/bf00544369
Abstract
Summary Interferon is currently being evaluated for the treatment of disseminated cancer and viral diseases. Alpha interferons have shown to be effective in the treatment of a number of malignancies. Recombinant leukocyte A interferon (rIFN-αA) is an alpha interferon produced by recombinant DNA techniques. A kinetic evaluation of rIFN-αA following intravenous and intramuscular administration has not been adequately defined. The present study was designed to evaluate the kinetics of rIFN-αA following intravenous and intramuscular administration of 3, 9 or 18×106 units to patients with disseminated cancer. A preliminary report of this study was presented at the meeting of the American Society for Clinical Pharmacology and Therapeutics in San Diego, March 1983 (1).Keywords
This publication has 1 reference indexed in Scilit:
- Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injectionClinical Pharmacology & Therapeutics, 1984